Oppenheimer Asset Management Inc. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Oppenheimer Asset Management Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$83.14 - $145.99 $25,690 - $45,110	-309 Reduced 3.89%	7,644 $1.11 Million
Q1 2022 May 12, 2022	SELL	$110.08 - $142.92 $2,201 - $2,858	-20 Reduced 0.25%	7,953 $943,000
Q4 2021 Feb 02, 2022	BUY	$99.73 - $148.48 $572,549 - $852,423	5,741 Added 257.21%	7,973 $1.1 Million
Q3 2021 Nov 12, 2021	SELL	$98.85 - $138.91 $6,524 - $9,168	-66 Reduced 2.87%	2,232 $310,000
Q2 2021 Aug 03, 2021	BUY	$65.78 - $105.02 $151,162 - $241,335	2,298 New	2,298 $223,000
Q1 2021 May 17, 2021	SELL	$64.07 - $91.75 $162,161 - $232,219	-2,531 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$65.07 - $98.24 $164,692 - $248,645	2,531 New	2,531 $217,000
Q2 2020 Aug 11, 2020	SELL	$29.01 - $74.23 $77,775 - $199,010	-2,681 Closed	0 $0
Q1 2020 May 08, 2020	SELL	$27.51 - $57.29 $3,961 - $8,249	-144 Reduced 5.1%	2,681 $91,000
Q4 2019 Feb 07, 2020	SELL	$40.86 - $57.65 $776 - $1,095	-19 Reduced 0.67%	2,825 $154,000
Q3 2019 Oct 31, 2019	BUY	$37.38 - $49.47 $106,308 - $140,692	2,844 New	2,844 $119,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.